

## Bibliography

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361:1139-51.
2. Van Ganse E, Danchin N, Mahe I, et al. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation. *Stroke*. 2020;51:2066-2075.
3. Andersson NW, Svanstrom H, Lund M, et al. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. *Int J Cardiol*. 2018;268:113-119.
4. January CT, Wann S, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation*. 2019;140:e125-e151.
5. Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update. Comparative Effectiveness Review No. 214. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2015-00004-I for AHRQ and PCORI.) AHRQ Publication No. 18(19)-EHC018-EF. PCORI Publication No. 2018-SR-04. Rockville, MD: Agency for Healthcare Research and Quality; October 2018. Posted final reports are located on the Effective Health Care Program search page. <https://doi.org/10.23970/AHRQEPCCER214>.
6. Chen A, Stecker E, Warden BA. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. *J Am Heart Assoc*. 2020;9(13):e107559.
7. Martin, K., Beyer-Westendorf, J., Davidson, B., Huisman, M., Sandset, P., & Moll, S. (2021). Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *Journal Of Thrombosis And Haemostasis*, 19(8), 1874-1882. doi: 10.1111/jth.15358
8. Kaplan, R., Tanaka, Y., Passman, R., Fine, M., Rasmussen-Torvik, L., & Vupputuri, S. et al. (2020). Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories. *Journal Of The American Heart Association*, 9(24). doi: 10.1161/jaha.120.017383
9. Witt, D., Nieuwlaat, R., Clark, N., Ansell, J., Holbrook, A., & Skov, J. et al. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Advances*, 2(22), 3257-3291. doi: 10.1182/bloodadvances.2018024893
10. January, C., Wann, L., Calkins, H., Chen, L., Cigarroa, J., & Cleveland, J. et al. (2019). 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation*, 140(2). doi: 10.1161/cir.0000000000000665
11. Patel M, Mahaffey K, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *N Engl J Med*. 2011;365(10):883-891.
12. Nutescu, E., 2022. Apixaban: Drug information. In: UpToDate. [online] Available at: <[https://www.uptodate.com/contents/apixaban-drug-information?search=APIXABAN&source=panel\\_search\\_result&selectedTitle=1~150&usage\\_type=panel&kp\\_tab=drug\\_general&display\\_rank=1](https://www.uptodate.com/contents/apixaban-drug-information?search=APIXABAN&source=panel_search_result&selectedTitle=1~150&usage_type=panel&kp_tab=drug_general&display_rank=1)> [Accessed 5 January 2022].
13. Nutescu, E., 2022. Rivaroxaban: Drug information. In: UpToDate. [online] Available at: <[https://www.uptodate.com/contents/rivaroxaban-drug-information?source=auto\\_suggest&selectedTitle=1~1---1~4---rivarox&search=rivaroxaban](https://www.uptodate.com/contents/rivaroxaban-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---rivarox&search=rivaroxaban)> [Accessed 5 January 2022]. Alshammari A, Altuwayjiri A, Alshaharani Z, et al. (October 19, 2020) Warfarin Dosing Requirement According to Body Mass Index. *Cureus* 12(10):e11047. DOI 10.7759/cureus.11047
14. Tello, K., Nguyen, S., Bultas, A., Armbruster, A., Greenwald, N., & Yancey, A. (2018). Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. *Therapeutic Advances In Cardiovascular Disease*, 12(8), 207-216. doi: 10.1177/1753944718781295
15. Wendte, J. (2019). Enoxaparin Rounding.
16. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2019;67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29. PMID: 30693946
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009 Sep 17;361(12):1139-51. Doi:10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: *N Engl J Med*. 2010 Nov 4;363(19):1877. PMID: 19717844.

18. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2\_suppl):e326S-e350S.
19. Eliquis package insert. [https://packageinserts.bms.com/pi/pi\\_eliquis.pdf](https://packageinserts.bms.com/pi/pi_eliquis.pdf). Accessed 2/11/22.
20. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PMID: 24251359.
21. Granger CB, Alexander JH, McMurray JJ, et al. Apixiban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011 Sep 15;365(11):981-82. Doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978.
22. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315-352
23. Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 3/4/22.
24. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957.
25. Pradaxa package insert. <https://docs.boehringer-ingenelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf>. Accessed 2/11/22.
26. Savaysa package insert. <https://daiichisankyo.us/prescribing-information-portal/getPICContent?productName=Savaysa&inline=true>. Accessed 2/11/22.
27. Xarelto package insert. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf>. Accessed 2/11/22.
28. Ansell, Jack, et al. Managing Oral Anticoagulation Therapy, Clinical and Operational Guidelines, 3rd edition. Facts and Comparisons; June 1, 2009
29. Dipiro, Joseph T, et al. Pharmacotherapy, a Pathophysiologic Approach, 7th edition. New York. McGraw-Hill; 2008. Chapter 21, Venous Thromboembolism; p. 347-353